Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 5, 2025Diabetes/Metabolism Research and ReviewsOpen Access

Effect of Glucagon‐Like Peptide‐1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

YCYizhu ChenYTYufei TangRYRui Yue

Discussion

Loading...

Member takes

Overview

Meta-analysis shows GLP-1 receptor agonists significantly reduce systolic blood pressure in type 1 diabetes, suggesting benefits for cardiometabolic health.

Key Points

  • GLP-1 receptor agonists significantly lowered systolic blood pressure, improving cardiometabolic outcomes.
  • The analysis included 21 randomized controlled trials with 3417 patients and confirmed marked benefits on risk factors.
  • Data showed reductions in LDL cholesterol and glycosylated haemoglobin, alongside weight loss in patients with T1DM.
  • These findings support the use of GLP-1 receptor agonists as an adjunctive therapy to standard insulin treatment.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/693231288e51979591dce4b2https://doi.org/10.1002/dmrr.70111
View Full Paper
Ask AI
Bookmark
Share